Endocrine Abstracts

We have previously demonstrated that in experimental Parkinson’s disease local production of oestrogens protects against striatal dopamine loss in vivo (Gillies GE. et al. Pharmacol Biochem Behav. 2004;78:513–22). As neurodegenerative disease is invariably accompanied by neuroinflammation, much interest has focused on oestrogen receptor (ER)-dependent suppression of inflammatory activation of microglia, the primary innate immune cell-type in the brain, ...

The main pathological finding in Parkinson’s disease (PD) is the loss of dopaminergic cells in the substantia nigra (SNc). Current dopamine-replacement therapies alleviate symptoms but do not prevent disease progression. The pathophysiology of PD is unknown, but oxidative stress and neuroinflammation have been implicated. A better understanding of the cause of dopaminergic cell death may lead to the discovery of new therapies that can slow disease progression.<p class...